Allogene Therapeutics, Inc.

ALLO

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001737287

None

No letter

4 of 13 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $415.9M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	short runway, thin data, degenerate in... not computable: fortress balance sheet
Inputs computable	4 of 13
Graded from	filings received through Mar 12, 2026 255 days before the rescan; latest periodic filing 10-Q received Nov 6, 2026
Last close	$0.62 2026-11-20; market equity $216.3M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 12, 2026

We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. We are developing a pipeline of "off-the-shelf" T cell product candidates that are designed to target and kill cancer cells in patients or eliminate pathogenic autoreactive cells in patients with autoimmune disorders. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient's use, as in the case of autologous T cells.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 45.2						
Gross profitability	not computable	32.8%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.6%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(8.6%)	(6.7%)	45.2	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 45.8					
Altman Z double-prime	(13.10)	0.31	68.0	705	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(3.61x)			
interest expense must exceed $100,000					
Current ratio	7.93x	2.68x	23.5	781	2025-12-31
Growth and financing, sleeve percentile 53.6					
Revenue growth, three-year compound	not computable	9.6%			
current value must be positive and the base must exceed $100,000					
Free cash flow growth, three-year compound	not computable	11.1%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	33.9%			
NOPAT must exceed $100,000					
Asset growth, three years	not computable	3.2%			
four consecutive annual observations are required					
Net share issuance, one year	12.2%	1.6%	53.6	626	2026-03-10

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 3.2 months
Thin data	4 of 13 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

What the price implies

at the 2026-11-20 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	29.0%	(1.7%)	69
Distance from 52-week high	(79.5%)	(33.0%)	10
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	(68.8%)	0.6%	11
Book value to price	1.81	0.29	93
Sales to price	0.00	0.38	0
Composite equity issuance, five years	90.2%	13.5%	81
Relative strength against the sector, log excess return	0.08	(0.19)	69
Twelve-month failure probability, CHS model	0.06%	0.06%	51

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$29.3M
Operating cash flow, four quarters	-$108.6M
Months of runway	3.2
Days since last periodic filing	16 (10-Q received Nov 6, 2026)
Median daily dollar volume, 63 sessions	$9.5M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$190.9M	2025-12-31	2026-03-12	10-K	26-017242
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$149.2M	2025-12-31	2026-03-12	10-K	26-017242
3	assets	us-gaap:Assets	$415.9M	2025-12-31	2026-03-12	10-K	26-017242
4	assets	us-gaap:Assets	$548.7M	2024-12-31	2026-03-12	10-K	26-017242
5	current assets	us-gaap:AssetsCurrent	$257.7M	2025-12-31	2026-03-12	10-K	26-017242
6	current liabilities	us-gaap:LiabilitiesCurrent	$32.5M	2025-12-31	2026-03-12	10-K	26-017242
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$2.0B	2025-12-31	2026-03-12	10-K	26-017242
8	operating income	us-gaap:OperatingIncomeLoss	-$209.3M	2025-12-31	2026-03-12	10-K	26-017242
9	book equity	us-gaap:StockholdersEquity	$292.5M	2025-12-31	2026-03-12	10-K	26-017242
10	liabilities	us-gaap:Liabilities	$123.4M	2025-12-31	2026-03-12	10-K	26-017242
11	operating income	us-gaap:OperatingIncomeLoss	-$258.2M	2020-12-31	2024-03-14	10-K/A	24-000018
12	interest expense	us-gaap:InterestExpense	$0	2020-12-31	2021-02-25	10-K	21-000009
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$0	2025-12-31	2026-03-12	10-K	26-017242
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$22,000	2024-12-31	2026-03-12	10-K	26-017242
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$95,000	2023-12-31	2025-03-13	10-K	25-000036
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$156,000	2022-12-31	2024-03-14	10-K	24-000021
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$386,000	2025-12-31	2026-03-12	10-K	26-017242
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$200.3M	2024-12-31	2026-03-12	10-K	26-017242
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$694,000	2024-12-31	2026-03-12	10-K	26-017242
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$237.7M	2023-12-31	2025-03-13	10-K	25-000036
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.5M	2023-12-31	2025-03-13	10-K	25-000036
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$220.5M	2022-12-31	2024-03-14	10-K	24-000021
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$5.2M	2022-12-31	2024-03-14	10-K	24-000021
24	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$12.4M	2025-12-31	2026-03-12	10-K	26-017242
25	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$190.9M	2025-12-31	2026-03-12	10-K	26-017242
26	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2025-12-31	2026-03-12	10-K	26-017242
27	current assets	us-gaap:AssetsCurrent	$303.4M	2024-12-31	2026-03-12	10-K	26-017242
28	current liabilities	us-gaap:LiabilitiesCurrent	$35.5M	2024-12-31	2026-03-12	10-K	26-017242
29	assets	us-gaap:Assets	$642.8M	2023-12-31	2025-03-13	10-K	25-000036
30	assets	us-gaap:Assets	$713.4M	2023-09-30	2024-03-14	10-K	24-000021
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	243,777,920	2026-03-10	2026-03-12	10-K	26-017242
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	217,264,738	2025-03-07	2025-03-13	10-K	25-000036

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.